<?xml version="1.0" encoding="UTF-8"?>
<p>In order to assess the impact of antivirals on the reactivation of EBV-DNA-emia, we analyzed the use of all antiviral drugs within 60 days before the onset of significant EBV-DNA-emia. Of 175 EBV infectious episodes, in 66 (37.7%) cases, the infection was preceded by another viral infection, including CMV (
 <italic>n</italic>=21), BKV (
 <italic>n</italic>=20), ADV (
 <italic>n</italic>=4), RV (
 <italic>n</italic>=3), FLUAV (
 <italic>n</italic>=1), HPIV (
 <italic>n</italic>=1), RSV (
 <italic>n</italic>=1), VZV (
 <italic>n</italic>=1), or multiple infections (BKV+CMV, 
 <italic>n</italic>=8; BKV+RV, 
 <italic>n</italic>=3; ADV+CMV, 
 <italic>n</italic>=1; ADV+HHV6, 
 <italic>n</italic>=1; ADV+RV, 
 <italic>n</italic>=1) within 7â€“56 (median 24) days before the diagnosis of EBV-DNA-emia. In 54/66 (81.8%) cases, a significant EBV-DNA-emia has occurred and treatment with rituximab was required. In 44/54 (81.5%) of these cases viral infections preceding EBV infection were treated with antiviral drugs, including: CDV (
 <italic>n</italic>=18), GCV (
 <italic>n</italic>=17), aciclovir (ACV) (
 <italic>n</italic>=1), oseltamivir (
 <italic>n</italic>=1) or drug combinations (FCV+GCV, 
 <italic>n</italic>=5; FCV+CDV, 
 <italic>n</italic>=2; GCV+CDV, 
 <italic>n</italic>=2). Antivirals were used for treatment of: CMV (
 <italic>n</italic>=16), BKV (
 <italic>n</italic>=11), ADV (
 <italic>n</italic>=4), FLUAV (
 <italic>n</italic>=1), VZV (
 <italic>n</italic>=1) or multiple infections (BKV+CMV, 
 <italic>n</italic>=7; BKV+RV, 
 <italic>n</italic>=1; ADV+CMV, 
 <italic>n</italic>=1; ADV+HHV-6, 
 <italic>n</italic>=1; ADV+RV, 
 <italic>n</italic>=1). Additionally, in 21/44 (47.7%) cases, development of significant EBV-DNA-emia occurred during GVHD (18 acute, 3 chronic). With respect to antiviral drugs, significant EBV-DNA-emia has developed in 24/242 (9.9%) GCV therapies, 22/153 (14.4%) CDV therapies, 9/100 (9.0%) FCV therapies, 1/12 (8.3%) ACV therapies and 1/13 (7.7%) of oseltamivir therapies.
</p>
